Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NC, Catovsky D, Strefford JC.

Blood. 2013 Jan 17;121(3):468-75. doi: 10.1182/blood-2012-05-429282. Epub 2012 Oct 18.

2.

Chronic lymphocytic leukemia: current and emerging treatment approaches.

Kay NE, Rai KR, O'Brien S.

Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 22):1-10; quiz 11-2. Review.

PMID:
17143256
3.

New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.

Filip AA.

Leuk Lymphoma. 2013 Sep;54(9):1876-81. doi: 10.3109/10428194.2013.769049. Epub 2013 Feb 20. Review.

PMID:
23343182
4.

Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.

Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM.

Cancer Genet. 2013 Mar;206(3):49-62. doi: 10.1016/j.cancergen.2013.01.003. Epub 2013 Mar 24. Review.

PMID:
23531595
5.

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.

Zent CS, Burack WR.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):119-24. doi: 10.1182/asheducation-2014.1.119. Epub 2014 Nov 18. Review.

PMID:
25696844
6.

SF3B1 mutations in chronic lymphocytic leukemia.

Wan Y, Wu CJ.

Blood. 2013 Jun 6;121(23):4627-34. doi: 10.1182/blood-2013-02-427641. Epub 2013 Apr 8. Review.

7.

Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.

Nabhan C, Raca G, Wang YL.

JAMA Oncol. 2015 Oct;1(7):965-74. doi: 10.1001/jamaoncol.2015.0779. Review.

PMID:
26181643
8.

Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.

Campregher PV, Hamerschlak N.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):271-6. doi: 10.1016/j.clml.2013.12.016. Epub 2013 Dec 30. Review.

PMID:
24548608
9.

Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.

Robak T, Lech-Maranda E, Robak P.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132. Review.

PMID:
20942624
10.

[Chronic lymphocytic leukemia: diagnosis and gene mutations].

Aoki S.

Rinsho Ketsueki. 2014 Oct;55(10):1981-8. Review. Japanese. No abstract available.

PMID:
25297763
11.

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.

Cazzola M, Rossi M, Malcovati L; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative.

Blood. 2013 Jan 10;121(2):260-9. doi: 10.1182/blood-2012-09-399725. Epub 2012 Nov 16. Review.

12.

Recurrent gene mutations in CLL.

Martínez-Trillos A, Quesada V, Villamor N, Puente XS, López-Otín C, Campo E.

Adv Exp Med Biol. 2013;792:87-107. doi: 10.1007/978-1-4614-8051-8_4. Review.

PMID:
24014293
13.

Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers.

Amaya-Chanaga CI, Rassenti LZ.

Best Pract Res Clin Haematol. 2016 Mar;29(1):79-89. doi: 10.1016/j.beha.2016.08.005. Epub 2016 Aug 10. Review.

PMID:
27742074
14.

Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.

Tausch E, Mertens D, Stilgenbauer S.

Oncol Res Treat. 2016;39(1-2):34-40. doi: 10.1159/000443906. Epub 2016 Jan 26. Review.

15.

Molecular genetics of high-risk chronic lymphocytic leukemia.

Rossi D, Gaidano G.

Expert Rev Hematol. 2012 Dec;5(6):593-602. doi: 10.1586/ehm.12.58. Review.

PMID:
23216591

Supplemental Content

Support Center